|
rs10757278
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
The hazard ratio associated with the high-risk genotype (a homozygote of high risk for ACS or a heterozygote) was: HR = 2.2 (1.15-4.2) for the rs10757278 polymorphism, HR = 2.7 (95% CI 1.3-5.4) for the rs4977574 one and HR = 2.3 (1.2-4.5) for the rs1333049 one (Cox proportional hazards model).
|
25105296 |
2014 |
|
rs10757278
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
The rs1333049, rs10757278 and rs4977574 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus that are associated with prevalence of acute coronary syndromes (ACS).
|
24069144 |
2013 |
|
rs10757278
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
The rs10757278 GG genotype was further associated with adverse cardiac outcomes after ACS.
|
23454037 |
2013 |
|
rs10757278
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
TexGen registry participants with ACS (n=2,067) or CABG (n=1,176) were evaluated, to assess whether 9p21 SNPs (rs1333049, rs2383206, rs10757278, rs10757274) were associated with recurrent MI (primary outcome), recurrent revascularization, or death (secondary outcomes) at approximately 3.2 years of follow-up.
|
22322877 |
2012 |
|
rs1333049
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
The hazard ratio associated with the high-risk genotype (a homozygote of high risk for ACS or a heterozygote) was: HR = 2.2 (1.15-4.2) for the rs10757278 polymorphism, HR = 2.7 (95% CI 1.3-5.4) for the rs4977574 one and HR = 2.3 (1.2-4.5) for the rs1333049 one (Cox proportional hazards model).
|
25105296 |
2014 |
|
rs1333049
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
The rs1333049, rs10757278 and rs4977574 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus that are associated with prevalence of acute coronary syndromes (ACS).
|
24069144 |
2013 |
|
rs1333049
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
Carriers of risk allele (C) for rs1333049</span> presented at an earlier age (62 vs. 63.5 years in non-carriers, P=0.0004) with more extensive disease (number of vessels with significant stenosis: 1.9 vs. 1.7 in non-carriers, P=0.001) in the ACS group.
|
22322877 |
2012 |
|
rs1333049
|
|
Acute Chest Syndrome
|
|
0.040 |
GeneticVariation
|
BEFREE |
After having confirmed that the at-risk C allele of rs1333049 was associated with index ACS in the UK and Belgian populations, we found that the rs1333049 at-risk C allele was significantly and independently associated with recurrent MI [age- and gender-adjusted hazard ratio (HR) 1.48, CI = 1.00-2.19, P = 0.048; and multivariable-adjusted HR 1.47, CI = 0.99-2.18; P = 0.053] and with recurrent MI or cardiac death (age- and gender-adjusted HR 1.58, CI = 1.00-2.48; P = 0.045; and multivariable adjusted HR 1.49, CI = 1.03-1.98; P = 0.028) within 6 months after an index ACS.
|
20231156 |
2010 |
|
rs4244285
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
The null allele in the CYP2C19 (rs4244285</span>) [odds ratio (OR)=5.317, 95% confidence interval (CI) 1.542-26.428, P=0.001] and CYP2C19 (rs4986893) (OR=4.295, 95%CI 1.312-17.517, P=0.013) is one of the causes of CR in patients with ACS in China.
|
31543510 |
2019 |
|
rs4244285
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
The aim of this study was to explore the individual effects of the CYP2C19 G681A polymorphism and omeprazole use and their interaction on clopidogrel responsiveness in acute coronary syndrome (ACS).
|
31658140 |
2019 |
|
rs4244285
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
We genotyped eight common PEAR1 SNPs (rs2768759, rs12566888, rs12041331, rs11264579, rs2644592, rs822441, rs822442, and rs4661012), also CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893) in 196 Chinese patients with ACS.
|
29407631 |
2018 |
|
rs4977574
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
The hazard ratio associated with the high-risk genotype (a homozygote of high risk for ACS or a heterozygote) was: HR = 2.2 (1.15-4.2) for the rs10757278 polymorphism, HR = 2.7 (95% CI 1.3-5.4) for the rs4977574 one and HR = 2.3 (1.2-4.5) for the rs1333049 one (Cox proportional hazards model).
|
25105296 |
2014 |
|
rs4977574
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
An interaction for increased ACS risk was found between carriers of the chromosome 9p21 variant rs4977574 and low omega-3 index (OR 1.57, 95% CI 1.07-2.32, p = 0.02), but this was not significant after correction for multiple testing.
|
24998078 |
2014 |
|
rs4977574
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
The rs1333049, rs10757278 and rs4977574 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus that are associated with prevalence of acute coronary syndromes (ACS).
|
24069144 |
2013 |
|
rs662
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
CYP2C19 and PON1 Q192R variants influence ADP-induced platelet inhibition by thrombelastography (TEG) in ACS patients with clopidogrel.
|
31772608 |
2019 |
|
rs662
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
The PON1 Q192R polymorphism status and PON1 paraoxonase and arylesterase activities of the healthy subjects and ACS patients were also determined.
|
25218815 |
2014 |
|
rs662
|
|
Acute Chest Syndrome
|
|
0.030 |
GeneticVariation
|
BEFREE |
The platelet aggregation, P-selectin expression and platelet/leukocyte conjugates as well as the clopidogrel response variability (evaluated by the VASP phosphorylation test and expressed as platelet reactivity index, PRI) were assessed in 74 ACS patients undergoing percutaneous coronary intervention (PCI) in relation to the PON-1 Q192R genotype and to serum HDL-cholesterol levels, and PON-1 (paraoxonase and arylesterase) activities.
|
22008470 |
2011 |
|
rs1042714
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
Gln27Glu polymorphism of ADRB2 influences exercise-induced vascular adaptation in patients with ACS.
|
28235084 |
2017 |
|
rs1042714
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
To evaluate the effect of ADRB1 Arg389Gly (1165 CG), Ser49Gly (145 AG), and ADRB2 Gly16Arg (46 GA), Gln27Glu (79 CG) genotypes on survival among patients discharged with prescribed beta-blockers after an acute coronary syndrome (ACS).
|
16189366 |
2005 |
|
rs1045642
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
The current meta-analysis suggests that ABCB1 C3435T polymorphism may contribute to the risk of CHD, especially for MI and ACS, among Caucasian populations.
|
24328528 |
2014 |
|
rs1045642
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our meta-analysis results indicated that ABCB1 C3435T</span> polymorphism may be associated with an increased risk of MI and ACS, especially among Asian populations (T allele vs. C allele: OR=1.40, 95% CI=1.31-1.49, ph=0.058).
|
25118983 |
2014 |
|
rs10757274
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
TexGen registry participants with ACS (n=2,067) or CABG (n=1,176) were evaluated, to assess whether 9p21 SNPs (rs1333049, rs2383206, rs10757278, rs10757274) were associated with recurrent MI (primary outcome), recurrent revascularization, or death (secondary outcomes) at approximately 3.2 years of follow-up.
|
22322877 |
2012 |
|
rs10757274
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, rs10757274 polymorphism was not associated with the classical risk factors either in control population or in ACS patients.
|
23249639 |
2012 |
|
rs1239681664
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
The current meta-analysis suggests that ABCB1 C3435T polymorphism may contribute to the risk of CHD, especially for MI and ACS, among Caucasian populations.
|
24328528 |
2014 |
|
rs1239681664
|
|
Acute Chest Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our meta-analysis results indicated that ABCB1 C3435T</span> polymorphism may be associated with an increased risk of MI and ACS, especially among Asian populations (T allele vs. C allele: OR=1.40, 95% CI=1.31-1.49, ph=0.058).
|
25118983 |
2014 |